Advertisement
Canada markets close in 4 hours 20 minutes

  • S&P/TSX

    21,918.10
    +32.72 (+0.15%)
     

  • S&P 500

    5,098.73
    +50.31 (+1.00%)
     

  • DOW

    38,203.13
    +117.33 (+0.31%)
     

  • CAD/USD

    0.7308
    -0.0015 (-0.20%)
     

  • CRUDE OIL

    84.04
    +0.47 (+0.56%)
     

  • Bitcoin CAD

    86,774.85
    -635.99 (-0.73%)
     

  • CMC Crypto 200

    1,324.38
    -72.15 (-5.17%)
     

  • GOLD FUTURES

    2,345.20
    +2.70 (+0.12%)
     

  • RUSSELL 2000

    1,994.59
    +13.47 (+0.68%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,918.56
    +306.80 (+1.97%)
     

  • VOLATILITY

    15.53
    +0.16 (+1.04%)
     

  • FTSE

    8,143.28
    +64.42 (+0.80%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6835
    +0.0014 (+0.21%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Valeant CEO 'disappointed' in Allergan poison pill: CNBC

Reuters
A sample of Botox is seen at the Long Island Plastic Surgical Group at the Americana Manhasset luxury shopping destination in Manhasset, New York September 30, 2010. REUTERS/Shannon Stapleton (Reuters)

(Reuters) - The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill. Allergan on Tuesday night said its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company. "We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday. (Reporting by Caroline Humer; Editing by Chizu Nomiyama)